Kazia Therapeutics Ltd ADR (KZIA) - Net Assets
Based on the latest financial reports, Kazia Therapeutics Ltd ADR (KZIA) has net assets worth $-8.30 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.06 Million) and total liabilities ($14.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kazia Therapeutics Ltd ADR liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.30 Million |
| % of Total Assets | -136.96% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.93% |
| 10-Year Change | -124.46% |
| Growth Volatility | 602.02 |
Kazia Therapeutics Ltd ADR - Net Assets Trend (1999–2025)
This chart illustrates how Kazia Therapeutics Ltd ADR's net assets have evolved over time, based on quarterly financial data. Also explore Kazia Therapeutics Ltd ADR assets under control for the complete picture of this company's asset base.
Annual Net Assets for Kazia Therapeutics Ltd ADR (1999–2025)
The table below shows the annual net assets of Kazia Therapeutics Ltd ADR from 1999 to 2025. For live valuation and market cap data, see market value of Kazia Therapeutics Ltd ADR.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $-8.30 Million | +17.13% |
| 2024-06-30 | $-10.02 Million | -183.13% |
| 2023-06-30 | $12.05 Million | -34.06% |
| 2022-06-30 | $18.27 Million | -51.72% |
| 2021-06-30 | $37.85 Million | +167.97% |
| 2020-06-30 | $14.12 Million | -0.31% |
| 2019-06-30 | $14.17 Million | -26.36% |
| 2018-06-30 | $19.24 Million | -24.06% |
| 2017-06-30 | $25.34 Million | -25.33% |
| 2016-06-30 | $33.93 Million | -23.51% |
| 2015-06-30 | $44.36 Million | +3041.71% |
| 2014-06-30 | $1.41 Million | -72.38% |
| 2013-06-30 | $5.11 Million | 0.00% |
| 2012-06-30 | $5.11 Million | +15.68% |
| 2011-06-30 | $4.42 Million | -66.45% |
| 2010-06-30 | $13.18 Million | -54.21% |
| 2009-06-30 | $28.77 Million | -19.21% |
| 2008-06-30 | $35.62 Million | -20.28% |
| 2007-06-30 | $44.68 Million | +0.18% |
| 2006-06-30 | $44.59 Million | -25.98% |
| 2005-06-30 | $60.25 Million | +25.98% |
| 2004-06-30 | $47.82 Million | +13.22% |
| 2003-06-30 | $42.24 Million | -21.88% |
| 2002-06-30 | $54.07 Million | -46.84% |
| 2001-06-30 | $101.72 Million | +92.90% |
| 2000-06-30 | $52.73 Million | +11.04% |
| 1999-06-30 | $47.49 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kazia Therapeutics Ltd ADR's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10157095600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $123.05 Million | % |
| Other Comprehensive Income | $3.10 Million | % |
| Other Components | $380.00K | % |
| Total Equity | $-8.30 Million | 100.00% |
Kazia Therapeutics Ltd ADR Competitors by Market Cap
The table below lists competitors of Kazia Therapeutics Ltd ADR ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Linc Limited
NSE:LINC
|
$64.90 Million |
|
Wooree Bio Co.Ltd
KQ:082850
|
$64.91 Million |
|
Urja Global Limited
NSE:URJA
|
$64.95 Million |
|
Catalyst Bancorp Inc
NASDAQ:CLST
|
$64.99 Million |
|
GameSparcs Co Ltd
TWO:6542
|
$64.84 Million |
|
Northview Acquisition Corp
NASDAQ:NVAC
|
$64.77 Million |
|
JR Invest SA
WAR:JRH
|
$64.76 Million |
|
Sumeeko Industries Co Ltd
TWO:2066
|
$64.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kazia Therapeutics Ltd ADR's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -10,017,000 to -8,301,000, a change of 1,716,000.
- Net loss of 20,702,000 reduced equity.
- New share issuances of 14,804,000 increased equity.
- Other comprehensive income decreased equity by 375,000.
- Other factors increased equity by 7,989,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.70 Million | -249.39% |
| Share Issuances | $14.80 Million | +178.34% |
| Other Comprehensive Income | $-375.00K | -4.52% |
| Other Changes | $7.99 Million | +96.24% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kazia Therapeutics Ltd ADR's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-06-30 | $4165.55 | $11.82 | x |
| 2000-06-30 | $3106.65 | $11.82 | x |
| 2001-06-30 | $118.77 | $11.82 | x |
| 2002-06-30 | $2791.54 | $11.82 | x |
| 2003-06-30 | $2170.60 | $11.82 | x |
| 2004-06-30 | $40.61 | $11.82 | x |
| 2005-06-30 | $2771.78 | $11.82 | x |
| 2006-06-30 | $2074.20 | $11.82 | x |
| 2007-06-30 | $1977.07 | $11.82 | x |
| 2008-06-30 | $1492.59 | $11.82 | x |
| 2009-06-30 | $1105.26 | $11.82 | x |
| 2010-06-30 | $520.30 | $11.82 | x |
| 2011-06-30 | $4.14 | $11.82 | x |
| 2012-06-30 | $3.39 | $11.82 | x |
| 2013-06-30 | $3.39 | $11.82 | x |
| 2014-06-30 | $45.78 | $11.82 | x |
| 2015-06-30 | $897.70 | $11.82 | x |
| 2016-06-30 | $380.38 | $11.82 | x |
| 2017-06-30 | $259.52 | $11.82 | x |
| 2018-06-30 | $190.59 | $11.82 | x |
| 2019-06-30 | $118.28 | $11.82 | x |
| 2020-06-30 | $92.65 | $11.82 | x |
| 2021-06-30 | $160.79 | $11.82 | x |
| 2022-06-30 | $68.96 | $11.82 | x |
| 2023-06-30 | $32.69 | $11.82 | x |
| 2024-06-30 | $-20.89 | $11.82 | x |
| 2025-06-30 | $-7.58 | $11.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kazia Therapeutics Ltd ADR utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49290.48%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-66.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | -35.96% | -88.37% | 0.35x | 1.18x | $-21.83 Million |
| 2000 | -25.94% | -51.14% | 0.41x | 1.23x | $-18.95 Million |
| 2001 | -41.93% | -72.39% | 0.49x | 1.18x | $-52.82 Million |
| 2002 | -27.51% | -74.83% | 0.32x | 1.16x | $-19.99 Million |
| 2003 | -24.99% | -31.63% | 0.65x | 1.21x | $-14.58 Million |
| 2004 | -27.90% | -76.49% | 0.21x | 1.72x | $-16.98 Million |
| 2005 | -21.64% | -69.47% | 0.26x | 1.19x | $-17.88 Million |
| 2006 | -38.22% | -120.15% | 0.26x | 1.20x | $-20.47 Million |
| 2007 | -49.25% | -115.53% | 0.34x | 1.27x | $-24.06 Million |
| 2008 | -66.03% | -152.55% | 0.31x | 1.41x | $-23.32 Million |
| 2009 | -79.94% | -169.80% | 0.29x | 1.60x | $-21.30 Million |
| 2010 | -110.33% | -124.60% | 0.51x | 1.72x | $-13.46 Million |
| 2011 | -153.65% | -320.89% | 0.16x | 3.01x | $-6.92 Million |
| 2012 | 37.67% | 86.52% | 0.17x | 2.59x | $961.50K |
| 2013 | -29.66% | -96.58% | 0.12x | 2.59x | $-1.38 Million |
| 2014 | -494.27% | -8583.13% | 0.02x | 3.08x | $-7.62 Million |
| 2015 | -15.98% | -8020.89% | 0.00x | 1.03x | $-11.61 Million |
| 2016 | -35.55% | -296.29% | 0.11x | 1.05x | $-15.46 Million |
| 2017 | -42.11% | -121.42% | 0.24x | 1.42x | $-13.20 Million |
| 2018 | -31.38% | -46071.10% | 0.00x | 1.46x | $-7.96 Million |
| 2019 | -72.35% | -656230.03% | 0.00x | 1.49x | $-11.69 Million |
| 2020 | -88.27% | -1261.75% | 0.04x | 1.63x | $-13.88 Million |
| 2021 | -22.25% | -55.46% | 0.26x | 1.53x | $-12.21 Million |
| 2022 | -136.88% | -250140.00% | 0.00x | 1.96x | $-26.84 Million |
| 2023 | -169.84% | -3687419.82% | 0.00x | 2.33x | $-21.67 Million |
| 2024 | 0.00% | -1160.23% | 0.11x | 0.00x | $-25.78 Million |
| 2025 | 0.00% | -49290.48% | 0.01x | 0.00x | $-19.87 Million |
Industry Comparison
This section compares Kazia Therapeutics Ltd ADR's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kazia Therapeutics Ltd ADR (KZIA) | $-8.30 Million | -35.96% | N/A | $64.84 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more